JPWO2015137056A1 - グルタミン酸による動脈管開存症の予防又は治療 - Google Patents
グルタミン酸による動脈管開存症の予防又は治療 Download PDFInfo
- Publication number
- JPWO2015137056A1 JPWO2015137056A1 JP2016507411A JP2016507411A JPWO2015137056A1 JP WO2015137056 A1 JPWO2015137056 A1 JP WO2015137056A1 JP 2016507411 A JP2016507411 A JP 2016507411A JP 2016507411 A JP2016507411 A JP 2016507411A JP WO2015137056 A1 JPWO2015137056 A1 JP WO2015137056A1
- Authority
- JP
- Japan
- Prior art keywords
- glutamic acid
- ductus arteriosus
- patent ductus
- salt
- glutamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003278 patent ductus arteriosus Diseases 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title claims description 9
- 230000002265 prevention Effects 0.000 title claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title description 54
- 229930195712 glutamate Natural products 0.000 title description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 52
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 39
- 239000004220 glutamic acid Substances 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 9
- 230000003449 preventive effect Effects 0.000 abstract description 5
- 241000700159 Rattus Species 0.000 description 23
- 210000003754 fetus Anatomy 0.000 description 18
- 102000018899 Glutamate Receptors Human genes 0.000 description 17
- 108010027915 Glutamate Receptors Proteins 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000001605 fetal effect Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000002028 premature Effects 0.000 description 9
- 210000001147 pulmonary artery Anatomy 0.000 description 9
- 210000000709 aorta Anatomy 0.000 description 8
- 210000004291 uterus Anatomy 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 229940049906 glutamate Drugs 0.000 description 6
- ZUINPPQIQARTKX-UHFFFAOYSA-N 1-Naphthylacetylspermine Chemical compound C1=CC=C2C(CC(=O)NCCCNCCCCNCCCN)=CC=CC2=C1 ZUINPPQIQARTKX-UHFFFAOYSA-N 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 208000018773 low birth weight Diseases 0.000 description 5
- 231100000533 low birth weight Toxicity 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 3
- 229960001289 prazosin Drugs 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 108010005456 AMPA 4 glutamate receptor ionotropic Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100030668 Glutamate receptor 4 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UUDAMDVQRQNNHZ-YFKPBYRVSA-N (2s)-2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid Chemical group CC=1ON=C(O)C=1C[C@H](N)C(O)=O UUDAMDVQRQNNHZ-YFKPBYRVSA-N 0.000 description 1
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
(1)グルタミン酸又はその塩を有効成分として含有する、動脈管開存症の予防薬又は治療薬。
(2)医薬的に有効な量のグルタミン酸又はその塩を被験者に投与することを含む、動脈管開存症を予防及び/又は治療する方法。
(3)動脈管開存症の予防及び/又は治療のためのグルタミン酸又はその塩の使用。
(4)動脈管開存症を予防及び/又は治療する方法に使用するためのグルタミン酸又はその塩。
本明細書は、本願の優先権の基礎である日本国特許出願、特願2014‐050206の明細書および/または図面に記載される内容を包含する。
また、本発明は、医薬的に有効な量のグルタミン酸又はその塩を被験者に投与することを含む、動脈管開存症を予防及び/又は治療する方法を提供する。
さらに、本発明は、動脈管開存症の予防及び/又は治療のためのグルタミン酸又はその塩の使用を提供する。
さらにまた、本発明は、動脈管開存症を予防及び/又は治療する方法に使用するためのグルタミン酸又はその塩を提供する。
〔実施例1〕定量RT-PCR(図1)
交配日が確定されている妊娠ラットを日本エスエルシーより購入し、交配日より算出された日程(胎生19日及び21日)で全身麻酔の後、帝王切開で胎仔を摘出した。胎仔動脈管(DA)組織および大動脈(AO)組織から作製したcDNAをテンプレートとしてRT-PCRによりグルタミン酸AMPA型受容体の4種のサブユニットGluR1、GluR2、GluR3およびGluR4の発現解析を行った。
GluR1:Forward: 5’- tcctgttgacacatccaatca-3’(配列番号1) Reverse: 5’- ccgttacctgccagttcttc-3’ (配列番号2)
GluR2:Forward: 5’- cagtcaccaatgctttctgc-3’ (配列番号3) Reverse: 5’- tgctcctttgaggtcaggtc -3’ (配列番号4)
GluR3:Forward: 5’- gcttcgttttaggcgtagca -3’ (配列番号5) Reverse: 5’- gctcctgaaccgtgtttctc -3’ (配列番号6)
GluR4:Forward: 5’ - cgatttggagggcataaaaa-3’ (配列番号7) Reverse: 5’- agaggcattgaagacgatgg -3’ (配列番号8)
学内倫理委員会の同意を得て、外科手術で摘除されたヒト動脈管大動脈移行部をホルマリン固定した後にパラフィン切片を作製した。作製したパラフィン切片から脱パラフィン操作を行った後に抗GluR1抗体(Sigma-Aldrich,USA)を反応させた後に二次抗体で標識し、動脈管でのGluR1サブユニットの発現を検討した。大動脈に比べて血管に厚みがあることなどで動脈管組織であることがわかる。この血管外膜側の血管周囲神経に一致してGluR1サブユニットが発現していることを確認した。
胎生21日のWistar ratを麻酔下で開腹し、以下の4群の肺動脈管腔径、動脈管(DA)腔径の計測を行った。
(1)子宮外からラット胎仔に生理食塩水(NS)200μlを胎仔腹腔内に投与したのちに一旦閉腹し30分後にラット胎仔を娩出。
(2)子宮外からラット胎仔に0.7%グルタミン酸水溶液(Glu)200μlを胎仔腹腔内に投与したのちに一旦閉腹し30分後にラット胎仔を娩出。
(3)子宮外からラット胎仔にAMPA型グルタミン酸受容体阻害薬NASPM(1μg/50μl)を投与し、更に15分後に0.7%グルタミン酸水溶液(Glu)200μlを胎仔腹腔内に投与したのちに一旦閉腹し30分後にラット胎仔を娩出。
(4)子宮外からラット胎仔にAMPA型グルタミン酸受容体阻害薬NASPM (10μg/50μl)を投与し、更に15分後に0.7%グルタミン酸水溶液(Glu)200μlを胎仔腹腔内に投与したのちに一旦閉腹し30分後にラット胎仔を娩出。
胎生21日のWistar ratを麻酔し、帝王切開で胎仔を摘出した。摘出した胎仔に200μlの0.7%グルタミン酸(Glu)水溶液またはdouble distilled water(DDW)を腹腔内投与した後に37℃のホットプレートで30分間観察した。その後心腔穿刺によりラット血液を採取し血漿分離を行った後に、血中アミノ酸分析をhigh-performance liquid chromatography/electrospray ionization/ mass spectrometry methodを用いて行った。
胎生21日のWistar ratを麻酔下で開腹し、以下の4群の肺動脈管腔径、動脈管腔径の計測を行った。
(1)子宮外からラット胎仔に生理食塩水(NS)200μlを胎仔腹腔内に投与したのちに一旦閉腹し30分後にラット胎仔を娩出。
(2)子宮外からラット胎仔に0.7%グルタミン酸水溶液(Glu)200μlを胎仔腹腔内に投与したのちに一旦閉腹し30分後にラット胎仔を娩出。
(3)子宮外からラット胎仔にアドレナリン受容体阻害薬prazosin(1μg/50μl)を投与し、更に15分後に0.7%グルタミン酸水溶液(Glu)200μlを胎仔腹腔内に投与したのちに一旦閉腹し30分後にラット胎仔を娩出。
実施例3と同様の方法で評価した。結果を図5に示す。グラフの縦軸は動脈管管腔径と肺動脈管腔径の比を表している。各二群間の有意差検定にはt-testを用い、有意水準はP<0.001とした。
本明細書で引用した全ての刊行物、特許および特許出願をそのまま参考として本明細書にとり入れるものとする。
Claims (4)
- グルタミン酸又はその塩を有効成分として含有する、動脈管開存症の予防薬又は治療薬。
- 医薬的に有効な量のグルタミン酸又はその塩を被験者に投与することを含む、動脈管開存症を予防及び/又は治療する方法。
- 動脈管開存症の予防及び/又は治療のためのグルタミン酸又はその塩の使用。
- 動脈管開存症を予防及び/又は治療する方法に使用するためのグルタミン酸又はその塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014050206 | 2014-03-13 | ||
JP2014050206 | 2014-03-13 | ||
PCT/JP2015/054277 WO2015137056A1 (ja) | 2014-03-13 | 2015-02-17 | グルタミン酸による動脈管開存症の予防又は治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015137056A1 true JPWO2015137056A1 (ja) | 2017-04-06 |
JP6396424B2 JP6396424B2 (ja) | 2018-09-26 |
Family
ID=54071507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016507411A Active JP6396424B2 (ja) | 2014-03-13 | 2015-02-17 | グルタミン酸による動脈管開存症の予防又は治療 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6396424B2 (ja) |
WO (1) | WO2015137056A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007106698A (ja) * | 2005-10-13 | 2007-04-26 | Yokohama City Univ | ヒアルロン酸合成促進による内膜肥厚及びその利用 |
WO2011059075A1 (ja) * | 2009-11-13 | 2011-05-19 | 味の素株式会社 | グルタミン酸およびアルギニンの高含有製剤 |
-
2015
- 2015-02-17 WO PCT/JP2015/054277 patent/WO2015137056A1/ja active Application Filing
- 2015-02-17 JP JP2016507411A patent/JP6396424B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007106698A (ja) * | 2005-10-13 | 2007-04-26 | Yokohama City Univ | ヒアルロン酸合成促進による内膜肥厚及びその利用 |
WO2011059075A1 (ja) * | 2009-11-13 | 2011-05-19 | 味の素株式会社 | グルタミン酸およびアルギニンの高含有製剤 |
Non-Patent Citations (5)
Title |
---|
"藤田秀次郎,アミノ酸輸液の組成の違いが動脈管閉鎖に及ぼす作用の検討", 日本周産期・新生児医学会雑誌, vol. 48, no. 2, JPN6018033317, 2012, pages 4 - 1 * |
RYCKMAN, KELLI K. ET AL.: "Association of amino acids with common complications of prematurity", PEDIATRIC RESEARCH, vol. 73, no. 6, JPN6015018846, 2013, pages 700 - 705 * |
中西敏雄: "II.小児科領域 1.動脈管収縮弛緩の機序", ANNUAL REVIEW 循環器, JPN6015018849, 1998, pages 153 - 155 * |
河野寿夫: "動脈管開存症に対するインドメタシン静注用の使用", 臨床と薬物治療, vol. 15, no. 11, JPN6015018848, 1996, pages 977 - 979 * |
門間和夫: "胎生期動脈管の薬理学", 東京女子医科大学雑誌, vol. 71, no. 4, JPN6015018847, 2001, pages 263 - 269 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015137056A1 (ja) | 2015-09-17 |
JP6396424B2 (ja) | 2018-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lin et al. | Fundamentals of anaesthesia | |
Anand et al. | Studies on the hormonal regulation of fuel metabolism in the human newborn infant undergoing anaesthesia and surgery | |
TW201919601A (zh) | 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法 | |
Reynolds et al. | Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review | |
JP7002444B2 (ja) | 医薬 | |
Smith et al. | Fundamentals of anaesthesia | |
Van Den Akker et al. | Human fetal amino acid metabolism at term gestation | |
Ozcan et al. | Evaluation of plasma amino acid levels in preterm infants and their potential correlation with retinopathy of prematurity | |
JP6396424B2 (ja) | グルタミン酸による動脈管開存症の予防又は治療 | |
TW201924689A (zh) | 治療正常射血分率之心臟衰竭之方法 | |
US11752122B2 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated TGF-beta activation and signaling | |
Franco et al. | Oral management of Steinert's disease and role of anxiolysis | |
TW201210587A (en) | Medicinal agent for prevention and/or treatment of hepatocellular carcinoma | |
SKYBERG et al. | Defibrination syndrome in a newborn, and its treatment with exchange transfusion | |
Polito et al. | Adrenocortical cell tolerance to lipopolysaccharide: a new mechanism for critical illness related corticosteroid insufficiency | |
Gohil et al. | Cardiotoxicity Associated with Midazolam in a Patient with Diphtheria | |
US8273717B2 (en) | Inhibitor for perioperative blood sugar elevation | |
US20230355561A1 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta activation and fibrosis | |
EP2986301A1 (en) | Phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy | |
JPS6248622A (ja) | 癌転移抑制剤 | |
Shastry et al. | Newborn With Hypoglycemia | |
Kara et al. | Congenital hypothyroidism presenting with postpartum bradycardia | |
Naheed et al. | Transient hyperglycemia, impaired glucose tolerance and gestational diabetes mellitus (GDM) in preterm pregnant women receiving antenatal steroids | |
Filaretova et al. | PO-0024 Clinical Course Features Of Newborns With Congenital Heart Defects: 15 Years’ Experience Of Our Centre | |
Li et al. | Effects of maternal hypothyroidism on postnatal cardiomyocyte proliferation and cardiac disease responses of the progeny |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171114 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180828 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180829 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6396424 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |